Top States: CA | DC | FL | GA | MA | NC | NJ | NY | OH | TX | WA |

Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine – Treatments Not Yet Offered in U.S.

By :: Tue, 09 Aug 2011 04:58:11 -0400 EDT

treatments for cancerKIRKLAND, Wash., Aug. 9, 2011 (SEND2PRESS NEWSWIRE) — Many Americans – unsatisfied with traditional treatments for cancer, diabetes, osteoporosis, and other intractable diseases – are looking south for advanced remedies. “We’re struggling to keep up with demand,” says Dr. Oscar E. Castro, head of Regenerative Cellular Therapy (RCT – www.rctherapy.net ), of Puerto Penasco, Sonora, Mexico.

Located on the grounds of the luxury Bella Sirena resort ( www.rctherapy.net/bella-sirena-resort ), RCT focuses on regenerative cellular therapy and natural pharmaceutical-quality bio-medications to optimize one’s energy and cell nutrition.

These processes stimulate stem cells using peptides and peptones. The effect is to eradicate the signs and symptoms of diseases more quickly and more effectively than medulla stem cell protocols. Each of the treatments exerts an effective preventative and curative action. “This occurs because the peptide and peptone treatments allow us to specifically target the organ that is affected,” stated Dr. Castro.

The use of peptides and peptones stimulates the patient’s stem cells, bringing results with unparalleled speed and intensity. The treatments are non-invasive and do not present any risk to the patient’s health, nor are there any negative secondary side effects or allergic reactions.

RCT’s peptide and peptone laboratories have been in their fields for over thirty years. “These laboratories continue to develop new therapies which have succeeded in having the dysfunctional cells of the recipient regenerate for their repair and revitalization within the strictest and most rigorous controls exacted by bio-safety,” says Dr. Castro.

In addition to treating symptoms, RCT’s bio-medications empower one’s cell tissue structure and organs, avoiding the connection of the symptoms to the disease, thus making the body fit to withstand functional stress loads during the treatment. All of this is done through correcting the biological process of the disease’s source and its side effects.

The two treatments receiving the most attention at RTC are the Peptide and E+ Peptide Cancer Vaccine. These treatments are now being used to treat:
* Diabetes
* Anti-Aging
* Rheumatoid Arthritis
* Cirrhosis
* Cancer
* Scleroderma
* Leukemia
* Lupus
* Kidney Failure
* Osteoporosis.

RCT’s E+ Peptide Cancer Vaccine is the key to tumor destruction. By conducting an exchange of information through the p53 gene, the gene then orders cellular self-destruction rather than multiplication, a process called apoptosis.

RCT does not offer services stateside, but the procedures are common in other parts of the world. “Our treatments have the phone ringing off the hook,” says Dr. Castro, “and we’re developing a backlog to service as many patients as we can.”

More information is available at http://www.rctherapy.net and contact@rctherapy.net, 480-626-4845 (USA office) or 638-382-8011 (Mexico office). An informational brochure may be downloaded at http://www.rctherapy.net/thankyou/RCT-BROCHURE.pdf .

News Source: Regenerative Cellular Therapy :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

More Information:

Press Release Copr. © Regenerative Cellular Therapy (or “news source”) and Send2Press® Newswire. Permission granted for reproduction by news portals, aggregators and news indexes provided original attribution to this site and news source is retained. Cannot be used for commercial purposes/advertising or keyword marketing. All other rights reserved.

This press release has had 3,276 views so far.
http://www.send2press.com/newswire/2011-08-0809-001.shtml
 
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the "news source." The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this Web site) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or the Send2Press® Newswire service. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.